UNCLASSIFIED

AD NUMBER ADB282793 **NEW LIMITATION CHANGE** TO Approved for public release, distribution unlimited **FROM** Distribution authorized to U.S. Gov't. agencies only; Proprietary Info.; Jun 2002. Other requests shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott St., Ft. Detrick, MD 21702-5012. **AUTHORITY** USAMRMC ltr, 11 Mar 2003

AD	•

Award Number: DAMD17-01-1-0611

TITLE: Ex Vivo Expansion of Dendritic Cells for Breast Cancer

Treatment

PRINCIPAL INVESTIGATOR: Ronald L. Brown, Ph.D.

CONTRACTING ORGANIZATION: Quality Biological, Incorporated

Gaithersburg, Maryland 20879-5412

REPORT DATE: June 2002

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command

Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Jun 02). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER DOES NOTIN ANY THAN GOVERNMENT PROCUREMENT FACT THAT THE THE U.S. GOVERNMENT. THE OBLIGATE SUPPLIED THE DRAWINGS, GOVERNMENT FORMULATED OR NOT LICENSE SPECIFICATIONS, OR OTHER DATA DOES HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-01-1-0611

Organization: Quality Biological, Incorporated

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Carole B Christian	
8/23/02	

REPORT DOCUMENTATION PAGE

Form Approved OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE	3. REPORT TYPE AND	
June 2002	Final (1 Jun 0	
4. TITLE AND SUBTITLE		5. FUNDING NUMBERS
Ex Vivo Expansion of Dendritic Cells	for Breast	DAMD17-01-1-0611
Cancer Treatment		
6. AUTHOR(S)		
Ronald L. Brown, Ph.D.		
Ronard B. Brown, In.B.		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)		8. PERFORMING ORGANIZATION REPORT NUMBER
Quality Biological, Incorporated		HEI OHI HOMBER
Gaithersburg, Maryland 20879-5412		
Galthersburg, Maryrand 20079-5412		
E-Mail: brownr@qualitybiological.com		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(E	S)	10. SPONSORING / MONITORING
TICA NOTICE Description of Material Command		AGENCY REPORT NUMBER
U.S. Army Medical Research and Materiel Command		
Fort Detrick, Maryland 21702-5012	!	
11. SUPPLEMENTARY NOTES		
	0	
40 DIOTRIDITION / AVAILABILITY CTATEMENT		12L DISTRIBUTION CODE
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government agenci	es only	12b. DISTRIBUTION CODE
(proprietary information, Jun 02). Other request		
document shall be referred to U.S. Army Medical R		
Materiel Command, 504 Scott Street, Fort Detrick,	Maryland 21702-5	5012.
13. ABSTRACT (Maximum 200 Words)		

The overall goal of this project was to develop a clinical-grade serum-free medium that specifically supported dendritic cell (DC) formation and antigen presentation. In two separate series of experiments we have characterized a serum-free medium that supports the ex vivo proliferation of DCs as well as their antigen presenting ability. In the first series of experiments we used ${\rm CD34^+}$ cells derived from mobilized peripheral blood stem cells and differentiated them to DCs in the presence of the cytokines GM-CSF, IL-4 and ${\rm TNF}\alpha$, although the serum-free medium supported this process it yielded only a small percentage of the DCs (3-5%) that are too few in number for clinical protocols. In a second series of experiments we used this same QBI serum-free formulation and differentiated DCs from normal monocytes that yielded over 80% of the population positive for the DC immunophenotype. This compared nearly equivalent in both number and antigen presenting ability to a proprietary serum-free medium developed specifically for lymphocyte proliferation and used in DC clinical trials. Future experiments are designed at optimizing this medium and evaluating other nutritional factors, cytokines and culture conditions to yield optimal DCs both in terms of number and function.

14. SUBJECT TERMS Ex Vivo, serum-free me cancer	15. NUMBER OF PAGES 10 16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

Table of Contents

Cover	
SF 298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	9
Reportable Outcomes	9
Conclusions	9
References	9
Appendices	9

INTRODUCTION:

The goal of this study was to develop clinically relevant culture conditions that support ex vivo expansion of dendritic cells (DCs) as well as their function in antigen presentation. Serum contains numerous unknown and ill-defined components as well as the potential to contain adventitious agents. The use of serum-free components can circumvent many of these difficulties. Presently the only serum-free media used to culture DCs was developed for other cell types and not specifically for DC proliferation/differentiation. The development of a clinical-grade serum-free medium specifically for DCs is necessitated by the technological difficulties in generating adequate numbers of highly purified DCs.

BODY:

ς.

Our initial experiments involved culturing CD34⁺ cells from mobilized peripheral blood. Peripheral blood progenitor cells (PBPCs) from mobilized breast cancer patients were purchased from Bio-Whittaker (Walkersville, MD). The CD34⁺ cells were isolated using Isolex-300i columns (Baxter, Inc., Deerfield, Illinois). The cells were assayed for CD34⁺ purity and are typically in the range of 90-95% pure. The CD34⁺ (2 x 10⁵ ml) were cultured for 2-3 weeks at 37°C, in a fully humidified incubator containing 5% CO₂ and air, in either alpha-modified Eagles medium (αMEM) or Iscove's modified Eagel's medium (IMEM) plus 10-20% fetal bovine serum (FBS) or QBI's initial serum-free medium comprised of Iscove's modified Dulbecco's medium (IMDM) plus 4 mg/ml HSA, 300 μg/ml human transferrin, and 0.48 U/ml human recombinant insulin. Each media was supplemented with 50 ng/ml GM-CSF, 25 ng/ml IL-4 and 10 ng/ml tumor necrosis factor-α (TNF-α) (R&D Systems, Minneapolis, Minnesota). Cells were harvested as noted and analyzed for dendritic cell surface markers. Tables I and II represent data from flow cytometric analysis of three separate experiments illustrating that the serum-free culture system was able to support the differentiation of CD34⁺ cells to cells expressing the dendritic markers, especially Lin DR⁺/CD11c⁺ and Lin DR⁺/CD80⁺.

Table I. Two separate experiments comparing dendritic cell differentiation in alpha-MEM with 20% FBS compared to QBI's initial serum-free formulation. Each media contained the cytokines: GM-CSF, IL-4 and TNF-α.

		Alpha-MI	EM + 20%	FBS (1 x	10 ⁶ cells)	QB	I Initial F	ormulatio	n (1 x 106	cells)
Markers	Expt	Day 7	Day 10	Day 14	Day 17	Expt	Day 7	Day 10	Day 14	Day 1
Lin-/DR+/1a+	1	11.1	18.7	4.7	3.5	1	1.5	0.1	1.3	0.4
	2	8.6	17.6	7.7		2	0.2	0.4	0.9	0.8
Lin-/DR+/11c+	1	10.1	19.5	10.2	12.9	1	0.3	1.5	7.2	3.6
	2	7.8	23.2	16.6		2	0.2	2.0	7.2	4.5
Lin-/DR+/40+	1	10.2	27.8	10.6	12.9	1	0.9	1.2	5.9	2.6
	2	7.1	32.0	16.7		2	0.5	2.3	6.5	3.4
Lin-/DR+/80+	1	1.3	10.7	3	2.8	1	0.02	0.1	0.5	0.4
	2	0.5	9.5	4.5		2	0.01	0.3	0.4	0.5
Lin-/DR+/83+	1	0.5	5.8	0.6	0.8	1	0.001	0.01	0.1	0.03
	2	0.2	5.2	1.1		2	0.004	0.08	0.2	0.06
Lin-/DR+/86+	1	2.6	15.8	3.3	2.2	1	0.1	0.3	1.2	0.04
	2	1.7	14.1	4.4		2	0.02	0.5	1.2	0.07

Table II. A single experiment comparing dendritic cell differentiation in IMDM with 10% FBS compared to QBI's initial serum-free formulation. Each media contained the cytokines: GM-CSF, IL-4 and TNF-α.

IMDM+10% FBS (Total Cell Number x 10 ⁵)				QBI Initial Formulation (Total Cell Number x 10 ⁵)		
Markers	Day 7	Day 14	Day 21	Day 7	Day 14	Day 21
Lin-DR+1a+	2.1	5.0	1.9	0.6	1.4	0.0
Lin-DR+11c+	15.5	16.8	3.8	4.3	4.5	3.6
Lin-DR+40+	0.2	0.0	0.8	0.3	0.2	0.0
Lin-DR+80+	3.1	6.3	4.4	1.1	2.0	0.54
Lin-DR+83+	0.1	0.1	0.2	0.1	0.2	0.0
Lin-DR+86+	9.1	10.2	5.9	4.3	5.4	2.1
Lin-DR+123+	42.7	8.6	7.6	17.0	5.6	1.1

In a third experiment we evaluated the expansion and differentiation of mobilized peripheral blood CD34⁺ cells to functional dendritic cells. Again, peripheral blood progenitor cells (PBPCs) from mobilized breast cancer patients were purchased from Bio-Whittaker (Walkersville, MD). The CD34⁺ cells were isolated using Isolex-300i columns (Baxter, Inc., Deerfield, Illinois). The cells were assayed for CD34⁺ purity and are typically in the range of 90-95% pure. The CD34⁺ (2 x 10⁵ ml) were cultured for 2-3 weeks at 37°C, in a fully humidified incubator containing 5% CO₂ and air, Iscove's modified Eagel's medium (IMEM) plus 10% fetal bovine serum (FBS) or QBI's initial serum-free formulation. Each media was supplemented with 50 ng/ml GM-CSF, 25 ng/ml IL-4 and 10 ng/ml tumor necrosis factor-α (TNF-α) (R&D Systems, Minneapolis, Minnesota). In both experiments cells were harvested after 3 weeks and analyzed for dendritic cell surface markers, Table III and IV. In both experiments the dendritic markers, Lin DR CD11c, had increased in serum containing media to 31.2 x 10⁵ and 4.4 x 10⁵ cells, respectively and in the QBI's initial serum-free formulation to 10.2×10^5 and 14.0×10^5 cells, respectively. Such data again indicates that both culture systems supported DC maturation, although, it takes 7 to 10 days longer in the serum-free medium as previously reported.

Table III

٠, .

IMDM+ 10% FBS (Total Cell Number x 10 ⁵)	Initial Formulation (Total Cell Number x 10 ⁵)
Markers	Day 22	Day 22
Lin-DR+la+	1	0.8
Lin-DR+11c+	31.2	10.2
Lin-DR+40+	0.2	2.4
Lin-DR+80+	1.9	8.9
Lin-DR+83+	0	1.5
Lin-DR+86+	3.5	11.6
Lin-DR+123+	10.7	1.2

Table IV

₹.

IMDM+ 10% FBS (7	Total Cell Number x 10 ⁵)	Initial Formulation (Total Cell Number x 10 ⁵)
Markers	Day 25	Day 25
Lin-DR+1a+	0.2	1.4
Lin-DR+11c+	4.4	14.0
Lin-DR+40+	0	0.5
Lin-DR+80+	0	9.9
Lin-DR+83+	0	6.9
Lin-DR+86+	.01	11.6
Lin-DR+123+	0.5	2.4

Tables III and IV: Two separate experiments comparing dendritic cell differentiation at the noted culture times in IMDM with 10% FBS versus QBI initial serum-free formulation each media contained the cytokines: GM-CSF, IL-4 and TNF-α.

The dendritic cells from this last experiment (Table IV) were evaluated in a mixed allolymphocyte assay. Briefly, lymphocytes (1 x $10^5/0.1$ ml) were cultured with different dilutions of irradiated (1500 RAD) dendritic cells (beginning at 1 x $10^5/0.1$ ml) in IMDM + 10% AB serum for six days. At the end of this time frame we added 0.7 μ C; H³-thymidine to each well and incubated an additional 12 hours, then counted. Figure 1 represents the fold stimulation using the DCs cultured in serum versus the initial serum-free formulation. The DCs cultured in serum-free medium yielded a typical stimulation index illustrating their ability to function in an MLR assay. The DCs cultured in serum containing medium did not have a significant stimulation index, most likely because DCs cultured in serum mature earlier, by day 14 of culture. In conclusion we have developed culture systems that yield DCs and determined that those cultured in serum-free medium for 3 weeks can support a mixed lymphocyte reaction.

Because relatively large yields of DCs can be derived from monocytes and can be easily obtained from patients/donors, we began the evaluation of our culture conditions for expansion of DCs using CD14⁺ selected or adherent cells from normal, healthy consented peripheral blood mononuclear cell (PBMC) volunteers. Adherent cells or CD14⁺ immunoselected (Miltenyi, CA) monocytes were collected from apheresis PBMC units (COBE Spectra, 9.3±2.2x10⁹ WBC, n=4) or whole blood buffy coats and cultured at 37°C for 7-8 days in XVIVO 15 (Biowhittaker, MD) or QBI's initial serum-free formulation containing cytokines. There are few serum-free media available for DC culture. XVIVO 15 media specifically formulated for macrophages and lymphocytes is currently being used in several protocols so was selected as a standard for DC production. Purity of CD14⁺ monocytes was >96% judged by flow cytometry (CD14⁺, CD3⁻, CD19°, CD56°, BD Biosciences Pharmingen, CA) (FACscan, Becton Dickinson, CA) and differential analysis (CellDyn, Abbott, IL). Adherent fractions were comprised mostly of CD14⁺ monocytes (71±10.6%). The cytokines GM-CSF (25 ng/ml) and IL-4 (25 ng/ml) (Pharmingen, CA) alone were added on day 0. To induce maturation TNF-α (30 ng/ml) was added to matching cultures on day 4. Both opened (6-well polystyrene culture plates) and clinical, closed (i.e., (Nexell Therapeutics, CA) culture bags using sterile-docking) systems were tested. Following the culture period, cells were harvested and assessed for viability using trypan blue exclusion and annexin-propidium iodide by flow cytometry (Coulter-Immunotech, FL). DC phenotype (i.e.,

flow analyses of surface markers CD1a, CD11c, CD14, CD80, CD86, CD83, MHC class I, II, mannose receptor, ILT3 and function (i.e., mixed lymphocyte response (MLR), antigen presentation) were also assessed. Table V shows high viabilities of cells after 7 days in culture without any added serum demonstrating that cells can be maintained under these conditions. QBI's initial serum-free culture formulation is able to support the differentiation of CD14⁺ monocytes to DCs. The cells expressed an "immature" phenotype, (CD14⁺CD80⁺CD86⁺DR⁺), following culture in GM-CSF+IL-4 and a "mature" phenotype by the appearance of CD83⁺ cells in cultures with GM-CSF+IL-4+ TNF-α added on day 4. The CD83⁺ expression levels differ between the media. It is not yet understood how these markers correlate with function; however, serum-free-cultured cells are able to stimulate and present antigen to T-cells despite different levels of expression as shown in Table VI.

Table V. Viability and Phenotype

٠,٠

Viability	Cytokine Treatment				
(n=4 per condition)	GM-CSF+IL4	GM-CSF+IL4+TNFα	No growth factors		
XVIVO15	92.4±7	82±11.8	90±20		
Initial Formulation	90±9	93±10	99±3		

Total mean based on media type (n=12 per media type): XVIVO15=88±13; Initial Formulation= 93±8 (ANOVA; p=0.208)

Phenotype: Cells cultured in GM-CSF+IL4 expressed high levels (>80%) CD1a, CD11c, CD40, CD80, CD86, HLADR, HLAABC in both media. GM-CSF+IL4+TNFα cultures also expressed the maturation marker CD83 (XVIVO15 85±8% and QBSF 40±22%)

Table VI. Function

	XVIVO 15		Initial Formulation		
Cytokine Treatment	MLR *	Stimulation Index**	MLR	Stimulation Index	
No growth factors	$6,833 \pm 2,498$	3±3	$7,766 \pm 1,934$	2 ± 2	
GM-CSF+IL4	28,635 ±14,489	9.2±2	$33,727 \pm 9,999$	5.3 ± 2	
GM-CSF+IL4+TNF□	$43,085 \pm 13,510$	6.5±2	34,320 ± 15,327	4.5 ± 2	
Total values based on media type (n=12 per media type)	25,271 (SE=5865)	6.2 ± 3	26,184	4 ± 1.7	

(n=4 per condition)

STATISTICS- MLR: ANOVA, p=0.461 Tukey; Antigen presentation: ANOVA, p=0.474

^{*}MLR=allogenic lymphocyte response-values are given as counts per minute (CPM) measured on gamma counter (Packard Instruments, CT) via uptake of 3H-thymidine after 5 day coculture of graded DC amounts from 10⁵ (shown) against 10⁵ T cells

^{**}Stimulation Index= Antigen presentation of tetanus toxoid (tet 2ug/ml) shown as CPM of DCs+ tet/DCs-tet

ALLO-MLA USING HUMAN DENDRITIC CELLS DIFFERENTIATED IN QBI's INITIAL SERUM-FREE FORMULATION OR IMDM WITH 10% FBS MEDIUM




Figure 1. DCs cultured in either serum (triangles) or serum-free medium (circles) then cultured with fresh lymphocytes (1 x 10⁵ per 0.1 ml) and varying dilutions of DCs (beginning at 1 x 10⁵ per 0.1 ml) in IMDM + 1-% AB serum. After six days of co-culture they were pulsed with H³-thymidine for 12 hours and counted

KEY RESEARCH ACCOMPLISHMENTS:

A clinical-grade serum free formulation that supports DC formation remains feasible.

REPORTABLE OUTCOMES:

The work presented herein has been used to apply for funding – Idea Proposal, Log # BC021256, entitled "Delineation of Ex Vivo Culture Condition for Breast Cancer Dendritic Cell Immunotherapy". This proposal will build on the above findings to develop an optimal clinical-grade serum-free medium for DC formation.

CONCLUSIONS:

The data reflects the ability of the QBI initial medium to specifically support ex vivo DC formation as well as function. The ex vivo culture of DCs derived from CD34⁺ cells is tenuous because of the low number of cells that have the DC immunophenotype. This is the case in both the serum-free media, as well as the serum containing medium suggesting that DCs formed from CD34⁺ cells may be to few in number for clinical use. This situation appears not to be the case using monocyte derived cells in which 80% of the ex vivo cultured population has the DC immunophenotype. It is now feasible to use the later system evaluate other components as: lipids, cholesterol, fatty acids, and different fractions of HSA for their affect on DC formation and antigen presentation. Once such an optimal clinical-grade formulation is developed further evaluation of various cytokine mixtures and concentrations, as well as the length of culture times to obtain optimum DC formation and function can be pursued.

REFERENCES:

None

APPENDICES:

None

DEPARTMENT OF THE ARMY



US ARMY MEDICAL RESEARCH AND MATERIEL COMMAND 504 SCOTT STREET FORT DETRICK, MARYLAND 21702-5012

REPLY TO ATTENTION OF:

MCMR-RMI-S (70-1y)

11 Mar 03

MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

- 1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.
- 2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLIS M. RINEHART

Deputy Chief of Staff for Information Management

ADB264655

ADB282172

ADB261548

ADB282212

ADB282747

ADB282213

ADB282133

ADB282748

ADB282793

ADB282229

ADB282720

ADB282132